Clinical stage biopharma small-cap, Harpoon Therapeutics has entered the spotlight with pharma giant, Merck agreeing to acquire the company for...
Read moreDetailsDecember's Consumer Price Index (CPI) data is in, and it brought a mixed bag of news for investors and consumers...
Read moreDetailsThe first-ever U.S. spot bitcoin ETFs began trading on Thursday, January 11th, 2024, marking a long-awaited milestone for the cryptocurrency...
Read moreDetailsIn a groundbreaking move, pharmaceutical giant Johnson & Johnson has set the stage for a significant leap forward in cancer...
Read moreDetailsCustomer experience player, TDCX has been recently buzzing on social media as its shares experienced a staggering surge following an...
Read moreDetailsAmidst Wayfair's recent struggles, two Chinese e-commerce giants, Shein and Temu, are emerging as potential acquirers, as per recent speculations.
Read moreDetails3D printing player, Stratasys finds itself at the center of attention as Nano Dimension makes a renewed takeover offer of...
Read moreDetailsAfter a week of mixed signals from policymakers and earnings reports, investors were eager to embrace a tech-fueled rally on...
Read moreDetailsSigma Lithium's recent talks with Chinese EV behemoth BYD have sparked a flurry of interest from industry titans like Tesla,...
Read moreDetailsAxonics witnessed its stock soar following the announcement of its acquisition by Boston Scientific in a staggering $3.7 billion deal.
Read moreDetailsThese Next Steps are EXTREMELY IMPORTANT because the only way to get our Featured Top Stock Alerts is to reply back to the message you just received by answering YES.
CLICK HERE TO REPLY BACK
YES ON YOUR CELL PHONE
To make sure you are in, please check your cell phone for a message from 16462224464 (make sure you save that number on your contacts under "StockTips") If you don't see the message check "Unknown Senders" on your phone.
If you did not receive the text message on your cell phone, then grab your phone right now and text the word "MOMO" to "16462224464"
© 2022 OpenEquity Research - Investment-Grade Research for the rest of us.
© 2022 OpenEquity Research - Investment-Grade Research for the rest of us.